McGuff Pharmaceuticals, Inc. – FDA 483, Jan 26, 2024
McGuff Pharmaceuticals, Inc. in Santa Ana, CA, a sterile drug manufacturer, received a Form 483 with six observations highlighting significant deficiencies across its quality systems. The inspection revealed inadequate investigations into manufacturing discrepancies, including decontamination cycle failures and particle monitoring excursions, and a failure to timely implement corrective actions. Further issues included an unreliable visual inspection program, unrecorded deviations from production procedures, insufficient employee training, and a lack of adherence to microbial monitoring test procedures and sanitation program documentation.
ID · 8072bd23-3409-41b9-b04a-7dcc8ccd7185
Document or profile
One record shows the event. A profile shows the pattern.
Buy this document for the source file and details behind this single event.
Choose full profile access to connect related records, sites, people, citations, and enforcement history in one view.